High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction

Title:High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction

Volume: 11 Issue: 1

Author(s): Andreja Trpkovic, Julijana Stanimirovic, Ivana Resanovic, Petar Otasevic, Danimir Jevremovic, Radak Djordje and Esma R. Isenovic

Affiliation:

Keywords: Atherogenesis, biomarker, cardiovascular disease, C-reactive protein, high sensitivity C-reactive protein, inflammation, prevention.

Abstract: It is now recognized that inflammatory processes regulate all stages of atherosclerosis, from disease initiation to thrombotic complications. C-reactive protein (CRP) is a plasmatic protein used as a general marker of inflammation. The high sensitivity C-reactive protein (hsCRP) refers to the measurement of CRP in blood samples using assays with sufficient sensitivity to quantify low (baseline) levels of this biomarker. Low-grade chronic inflammatory processes are linked to atherosclerosis and may be screened with the use of hsCRP, thus providing additional information in cardiovascular risk prediction. This review elaborates the role of CRP in atherogenesis and the value of hsCRP as a biomarker in cardiovascular risk prediction in both primary and secondary prevention setting.

Cite this article as:

Trpkovic Andreja, Stanimirovic Julijana, Resanovic Ivana, Otasevic Petar, Jevremovic Danimir, Djordje Radak and Isenovic R. Esma, High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction, Current Pharmaceutical Analysis 2015; 11 (1) . https://dx.doi.org/10.2174/1573412910666140822003911